QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS TechnologyBusiness Wire • 07/01/21
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification LaboratoriesBusiness Wire • 06/29/21
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing SolutionsBusiness Wire • 06/29/21
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing ExperimentsBusiness Wire • 06/21/21
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung CancerBusiness Wire • 05/28/21
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)Business Wire • 05/25/21
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021Business Wire • 05/17/21
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus AntibodiesBusiness Wire • 05/12/21
QIAGEN's (QGEN) CEO Thierry Bernard on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost RevenuesBenzinga • 05/04/21
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021Business Wire • 05/03/21
QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and DiagnosticsBusiness Wire • 04/29/21
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme BorreliosisBusiness Wire • 04/21/21